Cargando…

Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma

SIMPLE SUMMARY: The treatment of collecting duct carcinoma (CDC) remains unsatisfactory since this highly aggressive kidney cancer has an unfavorable clinical behavior. Due to the rarity of CDC a complete biological characterization of this disease is still lacking. The aim of our study is to provid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gargiuli, Chiara, Sepe, Pierangela, Tessari, Anna, Sheetz, Tyler, Colecchia, Maurizio, de Braud, Filippo Guglielmo Maria, Procopio, Giuseppe, Sensi, Marialuisa, Verzoni, Elena, Dugo, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230422/ https://www.ncbi.nlm.nih.gov/pubmed/34200770 http://dx.doi.org/10.3390/cancers13122903

Ejemplares similares

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
por: Raimondi, Alessandra, et al.
Publicado: (2019)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
por: Mennitto, Alessia, et al.
Publicado: (2020)

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
por: Dugo, Matteo, et al.
Publicado: (2015)

Response to Targeted Therapy in Urachal Adenocarcinoma
por: Testa, Isabella, et al.
Publicado: (2014)

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2021)

A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer
por: Gargiuli, Chiara, et al.
Publicado: (2022)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2020)

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience
por: Sepe, Pierangela, et al.
Publicado: (2019)

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
por: Bottiglieri, Achille, et al.
Publicado: (2022)

Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression
por: Cappelletti, Vera, et al.
Publicado: (2020)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic
por: Claps, M., et al.
Publicado: (2021)

Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients
por: Rinchai, Darawan, et al.
Publicado: (2021)

Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study
por: Dugo, Matteo, et al.
Publicado: (2019)

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2020)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Claudins in the Renal Collecting Duct
por: Leiz, Janna, et al.
Publicado: (2019)

Altered collecting duct adenylyl cyclase content in collecting duct endothelin-1 knockout mice
por: Strait, Kevin A, et al.
Publicado: (2007)

Predicting Molecular Models: Where Are We Going?
por: Ratta, Raffaele, et al.
Publicado: (2015)

The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial–mesenchymal transition, and immune response
por: Devecchi, Andrea, et al.
Publicado: (2018)

Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended
por: Giussani, Marta, et al.
Publicado: (2021)

Genomic profiling of collecting duct renal carcinoma
por: Chintala, Sreenivasulu, et al.
Publicado: (2016)

New common bile duct morphological subtypes: Risk predictors of common bile duct stone recurrence
por: Ji, Xu, et al.
Publicado: (2022)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review
por: Lo Russo, Giuseppe, et al.
Publicado: (2018)

Axl in ovarian cancer: a step forward for clinical breakthrough?
por: Sensi, Marialuisa, et al.
Publicado: (2016)

Risk prediction of common bile duct stone recurrence based on new common bile duct morphological subtypes
por: Saito, Hirokazu, et al.
Publicado: (2022)

miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators
por: Vergani, Elisabetta, et al.
Publicado: (2020)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
por: Tazi, El Mehdi, et al.
Publicado: (2011)

Nephron sparing surgery for metastatic collecting duct carcinoma
por: Kopeć, Norbert, et al.
Publicado: (2019)

A rare curative case of collecting duct carcinoma
por: Wu, Tielin, et al.
Publicado: (2021)

Editorial: Collection on renal disease, diabetes and cognitive performance
por: Franciotti, Raffaella, et al.
Publicado: (2023)

Papillary renal cell carcinoma and collecting duct carcinoma combination. A case report and review of synchronous renal cell carcinoma subtypes in the same kidney
por: Arık, Deniz, et al.
Publicado: (2015)

Synchronous Double Bile Duct Cancers with Distinct Genetic Features
por: Morita, Shinichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2qcamk29ch9e8vk3gfrbasto0f